UK: View From The Horizon: Artificial Intelligence And Cannabusiness In London

On May 16 the second edition of our new global series, Life Sciences and Health Care Horizons, took place in London featuring two panel discussions that focused on the challenges and opportunities in two of the sector's emerging markets: (1) Artificial Intelligence; and (2) Cannabusiness. We are excited to share the following highlights from London, and we look forward to future discussions as we forecast and help clients prepare for what's to come.

The rise of the machines – AI and digital health

Artificial Intelligence (AI) covers a number of subfields such as robotics, machine learning, natural language and speech processing and deep learning and at our London Life Sciences and Health Care Horizons event, the panel discussions looked at the potential benefits of using AI in the drug design process including improving success rates for the development of new drugs and reducing the length of time, and money, spent on the initial design phase. The panel also discussed some of the legal and ethical questions that might arise with the use of AI.

Imogen Ireland, Senior Associate in the firm's Intellectual Property practice, discussed how AI is being used to discover lead compounds for therapeutic use. . Imogen noted that a key factor in the use of AI is that it can gather and review data in enormous quantities very quickly – AI can "review and process, in a matter of hours, data that could take teams of scientists years." Imogen noted, however, that the use of AI in drug discovery is likely to raise some interesting legal and regulatory considerations. In patent law, for instance, a key issue is whether or not it is possible to patent AI output and, if it is, who owns the output? Related to this is the issue of disclosure – in other words, explained Imogen, how do you demonstrate to others that your AI-developed drug works? What sort of data do you have to do this? If you are relying on algorithms, who do these algorithms belong to, and are they confidential? Such issues could be relevant when filing a patent for the AI-developed drug, or working with regulators at the clinical trial stage.

Dr. Sandeep Shah, CEO of Tarilian Laser Technologies, provided a practical example of how companies are making use of AI and innovative technology to improve health. Dr. Shah described how his company is taking advantage of AI technologies such as deep learning and neural networks to find more effective ways of handling the diagnosis and treatment of hypertension. Dr. Shah noted that about 40% of the adult population is potentially affected by hypertension and current methods of measuring and monitoring the condition were generally short term and inconvenient for the patient. Dr. Shah discussed the development of new ways of monitoring utilising innovative medtech sensing and data insight to provide precision therapeutics which could be a game changer in terms of providing cheaper, more efficient monitoring of the condition long term.

Dr. Alan Payne, Honorary Professor at UCL and CIO of Cloudsolve, discussed data protection issues arising from the collection of personal data through health monitoring apps and devices. Dr. Payne discussed the importance of consent and of using clear language in describing how the data will be used. Dr. Payne also commented on the need to segment data, stripping away the individual identifying personal data from the core health data, which would allow companies to analyse the health data without infringing on the patient's ownership of their personal data.

How AI might shape the world of medicine and pharmaceuticals in the future was also a key point of discussion for the panel. Imogen Ireland suggested that AI could lead to an increased rate of drug discoveries and approvals which would be of benefit to patients – providing them with more options. Dr. Shah discussed how AI could assist with providing continuous monitoring of health conditions which could lead to the development of individualised doses and "the ability to dynamise change in the way we manage our medicines".

The panel finished up by reflecting on whether AI will ever be given personhood. Dr. Payne said this was "probably inevitable" as at some point it would be necessary to apply some sort of legal status and have some legal framework to deal with AI. Dr. Payne considered that a historic lack of trust in AI meant there was a need for legislation if AI was to be fully accepted.

A business up in smoke - Cannabusiness

Cannabis has a long history, its use being documented in China as far back as 2,400 years ago. Traditionally it was used as a food source, for its fibres and also for its psychoactive properties, however more recently there has been much discussion about its medicinal properties. This increased interest has triggered a wave of scientific research into the active compounds, including recent research suggesting that endocannabinoids can be produced during running, the so called 'runners high', as well as much debate about effective regulation. This session explored some of these ideas in more depth.

Dr. Marion Palmer, Senior Scientist at Hogan Lovells, kicked off the session with a look at the science behind cannabis and its medicinal properties. Cannabis contains a vast array of different chemicals, including flavonoids, steroids and phytocannabinoids, the concentrations of which vary according to species and growing conditions, and which can also be altered post-harvest by storage and treatments. The main endocannabinoids in the human body are AEA and 2-AG and they act by altering neurotransmission at the cannabinoid receptors; these receptors play important roles in a wide range of bodily functions such as pain, inflammation and epilepsy. THC is the psychoactive component, with a synthetic version being available commercially for use in cancer and anorexia treatment whereas CBD is non-psychoactive and is important in epilepsy treatment. Marion concluded by setting out that there is currently a lack of standardised protocols and methodologies for testing to assess the quality and constitution of cannabis products.

Jane Summerfield, Counsel in the firm's Global Regulatory practice, set out the UK regulatory framework for cannabis products covering every stage of the supply chain, from growing and R&D, through to the processing and sale of products. Three main areas of regulation are especially relevant; controlled drug regulation, product regulation and consumer regulation.

The Misuse of Drugs Act 1971 sets out the penalties for misuse of controlled drugs with cannabis listed as a Class B drug. The Misuse of Drugs Regulations 2001 set out conditions for lawful production, supply and possession of controlled drugs with cannabis listed in Schedule 1, meaning that possession and supply are prohibited unless the Home Office has issued a license. Cannabis-based medicines have recently been moved to Schedule 2 meaning that they can be prescribed subject to special conditions, however to date only a limited number of packs have reached UK market. Pure CBD products are outside the scope of the controlled drugs regime, but the onus is on the producer to show that no THC or other controlled substances are present.

In terms of product regulation, Jane explained that products containing CBD and which are used for a medical purpose are regulated as medicines, while many non-medical CBD products are regulated as foods or food supplements. Other CBD products can fall within cosmetics legislation or other categories such as veterinary medicines, depending on their composition and use.

Jane concluded by explaining the whole raft of consumer regulation that could be relevant when selling cannabis-based products to consumers, including on consumer rights, e-commerce/ distance selling and advertising .

Dan Brook, Partner in the firm's Intellectual Property practice, explained that there are exceptions to patentability, including on the grounds of immorality and for plant varieties, however over 1000 patents are currently granted for cannabis products. The immorality test was set during the 1993 Roundup case- the question to be asked is, 'is it abhorrent to EU society?' Dan also explained that the plant variety question had proved to be somewhat a political hot potato and concluded by explaining that whilst there appear to be mechanisms to prevent something like cannabis being patented, there really are no any special rules being implemented at present.

The panel concluded that Cannabis is likely to be a huge growth market with many companies already investing huge amounts. Understanding the regulatory environment is essential to success in this market.

Life Sciences and Health Care Horizons – Global Event Series

From spotting trends in digital health innovation to breakthrough cures and navigating fluid regulatory landscapes, the Hogan Lovells' Life Sciences and Health Care Horizons event series will span three continents and feature cutting-edge analysis, engaging panel discussions, and featured keynote speakers.

Read the highlights

30 April: Boston

16 May: London

Mark your calendars

27 June: Paris

30 Oct.: Tokyo

6 Nov.: Shanghai

13 Nov.: Northern California

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions